Welcome to our dedicated page for Gyre Therapeutics news (Ticker: GYRE), a resource for investors and traders seeking the latest updates and insights on Gyre Therapeutics stock.
Gyre Therapeutics, Inc. (Nasdaq: GYRE) is a San Diego-based biopharmaceutical company focused on fibrosis-first therapies, with its lead candidate Hydronidone targeting liver fibrosis and a commercial and development platform in the People’s Republic of China through Gyre Pharmaceuticals. The GYRE news feed highlights how the company advances anti-fibrotic drugs across liver and lung indications and how these efforts translate into clinical, regulatory and commercial milestones.
Investors following GYRE news can see updates on Hydronidone’s regulatory pathway in China, including its Breakthrough Therapy Designation, pivotal Phase 3 results in chronic hepatitis B-associated liver fibrosis and alignment with China’s Center for Drug Evaluation on a conditional approval NDA and priority review eligibility. News coverage also includes Gyre’s plans for U.S. development of Hydronidone in MASH-associated liver fibrosis, such as IND-related activities, planned Phase 2 trial design and supporting studies like hepatic impairment assessments.
Company announcements also report on the performance and expansion of Gyre’s commercial portfolio in the PRC, including ETUARY (pirfenidone capsules) for idiopathic pulmonary fibrosis, Etorel (nintedanib ethanesulfonate soft capsules) for systemic sclerosis-associated and progressive fibrosing interstitial lung disease, and Contiva (avatrombopag maleate tablets) for thrombocytopenia in adults with chronic liver disease and immune thrombocytopenic purpura. Additional news items cover pipeline progress for pirfenidone in pneumoconiosis and oncology-related pulmonary complications, F573 for acute/acute-on-chronic liver failure, F528 for COPD and F230 for pulmonary arterial hypertension.
On this page, readers can review press releases on quarterly and year-to-date financial results, public offerings of common stock, leadership and board changes, scientific conference presentations and major clinical trial milestones. Tracking GYRE news helps contextualize the company’s fibrosis-focused strategy, its China-based commercial engine and its U.S. development plans for Hydronidone.
Gyre Therapeutics reported first-quarter 2024 financial results, with $29.8 million in cash and cash equivalents as of March 31, 2024. The company's Phase 3 clinical trial of F351 for CHB-associated liver fibrosis in the PRC is on track, with data expected by early 2025. Gyre plans to initiate a Phase 2a trial for NASH-associated liver fibrosis in the U.S. in 2025. Additionally, Gyre acquired rights to assets related to nintedanib through Gyre Pharmaceuticals to enhance competitiveness. The company's ETUARY sales reached $26.9 million in Q1 2024, showing growth from the same period in 2023. Financially, Gyre had revenues of $27.2 million for the quarter ended March 31, 2024, with net income of $9.9 million and net income attributable to common stockholders of $7.5 million. Gyre also reported adjusted net income to provide additional insights for investors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.